Speeches by Cooper.

“Excellent. I thank my hon. Friend, who has nicely paid tribute to them. Well done. What has been so striking about the work we are doing is the level of local energy in our community. People care deeply about these spaces, and they want to see them thriving again. We have an opportunity to do that in a way that reflect…”

“Neha, do you have any reflections on that from a pharmacy point of view, in terms of the monitoring of side effects and how you are able to report it?”

“That is very interesting. In terms of online pharmacies are you seeing a proportionate reporting to the in-person pharmacies or are you seeing lesser reporting?”

“When you say you go out looking for it, what do you do?”

“What do they come in at for the QALY?”

“I appreciate that and I appreciate the prevalence issue. While you cannot take an accurate indicator of prevalence from reporting, again given the extensive licensing that MHRA has done over the years, is the reporting that you are seeing, taking into account the self-reporting nature of it and the private prescribing …”

“Okay, so just to be clear, you are not seeing any difference in the side effect profile from a type 2 diabetes patient using GLP-1s to a non-type 2 diabetes person using it for weight loss? The side effect profile is reasonably similar?”

“Just to be clear there, you are not seeing more side effect reporting for the new use of this established medicine than you would expect? Is it within expected parameters?”

“Given that GLP-1 products have not been used as weight loss tools for nearly as long as they have been used for diabetes type 2, are you concerned about an increase in side effects being reported as GLP-1s are used more frequently for weight loss?”

“The yellow card reporting has been around for a long time and there have been conversations about whether it is fit for purpose or they need to use something else. Your opinion is yellow card reporting is still the best way of assessing side effects coming forward or adverse impact?”

“We have heard that before.”

“It would be interesting to see those figures.”

“That is interesting. We will not go down this rabbit hole too much, but over the years have you found the yellow card reporting system by and large with your licensing of different medications a reasonably reliable indicator of when there are issues that need to be acted upon?”

“Yes.”

“Thanks, panel, for being here. I am going to focus on questions around side effects and NICE appraisal. I will start with Andy and the MHRA. GLP-1s as we know have a long-standing history. They have been used for more than a decade to treat type 2 diabetes so we are well aware of their profile in that regard. In terms …”

“Sorry, just to go back, because the public are watching, John, can you explain quickly what a QALY is?”

“That is very interesting. Again for the record, basically once NICE makes a positive recommendation, NHS service providers are required to make it available to patients within three months as a default, but there is an exception to that. Based on your recommendation, NHS England estimated that 2.8 million patients woul…”

“Sorry, John, we are time pressured. You came to an understanding with NHS England, which you have only done four times previously, that all the eligible population will be able to be prescribed Mounjaro for obesity within 12 years.”

“It is a pleasure to serve under your chairship, Mr Efford. I commend my hon. Friend the Member for Peterborough (Andrew Pakes) for his continued advocacy. As someone who lived down the road in Huntingdon for many years, I am delighted to hear that Peterborough lido is up and running again, which is fantastic. Lidos are…”

“So what did your world-leading process think about £15.2 billion over five years?”